EPISODE · Apr 15, 2025 · 37 MIN
From Mentee to CEO, Board Member and Mentor: Insights from Kerrie Brady
from Clinical Trialblazers · host Parexel
In this episode of Clinical Trialblazers, host Alberto Grignolo speaks with Kerrie Brady, Chairperson of Neurocentrx Pharmaceuticals and an Independent Board Member at Asklepion Pharmaceuticals and Invea Therapeutics. Kerrie reflects on her extensive career in the biotech and pharmaceutical industries, highlighting the importance of mentorship, leadership style, and navigating cultural transitions in global business. Kerrie also shares her insights on the complexities of board membership and the challenges of maintaining work-life balance in this fast-paced industry.We hope you enjoyed this episode of Clinical Trialblazers. Please take a moment to rate and review this podcast wherever you listen.Special thanks to our production partner, Wonder Media Network. Our producer is Brittany Martinez, our editor is Maddy Foley and our production assistant is Joia Putnoi. We hope you enjoyed this week’s episode of Clinical Trialblazers. Please take a moment to rate and review this podcast wherever you listen.Special thanks to our production partner, Wonder Media Network. Our producer is Brittany Martinez, our editor is Gianna Palmer and our production assistant is Joia Putnoi.
What this episode covers
In this episode of Clinical Trialblazers, host Alberto Grignolo speaks with Kerrie Brady, Chairperson of Neurocentrx Pharmaceuticals and an Independent Board Member at Asklepion Pharmaceuticals and Invea Therapeutics. Kerrie reflects on her extensive career in the biotech and pharmaceutical industries, highlighting the importance of receiving early mentorship, cultivating relationships of trust with investors, working with your Board of Directors, reasons for joining Boards, leadership style, and navigating cultural transitions in global business.
NOW PLAYING
From Mentee to CEO, Board Member and Mentor: Insights from Kerrie Brady
No transcript for this episode yet
Similar Episodes
Feb 24, 2025 ·17m
Feb 17, 2025 ·39m
Feb 10, 2025 ·87m